Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03554044
Title Talimogene Laherparepvec With Chemotherapy or Endocrine Therapy in Treating Participants With Metastatic, Unresectable, or Recurrent HER2- Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of California, San Francisco
Indications

Her2-receptor negative breast cancer

Therapies

Letrozole + Talimogene laherparepvec

Talimogene laherparepvec + Tamoxifen

Exemestane + Talimogene laherparepvec

Fulvestrant + Talimogene laherparepvec

Anastrozole + Talimogene laherparepvec

Nab-paclitaxel + Talimogene laherparepvec

Carboplatin + Gemcitabine + Talimogene laherparepvec

Paclitaxel + Talimogene laherparepvec

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.